IJSER Home >> Journal >> IJSER
International Journal of Scientific and Engineering Research
ISSN Online 2229-5518
ISSN Print: 2229-5518 5    
Website: http://www.ijser.org
scirp IJSER >> Volume 3,Issue 5,May 2012
Changes of lipoapoproteins and the Role of Statins of Patients with Terminal Chronic Renal Insuf-ficiency treated with repeated hemodialysis[
Full Text(PDF, )  PP.15-19  
Author(s)
Lutfi Zylbeari, Gazmend Zylbeari, Elita Masha, Zamira Bexheti, Merition Ballazhi, Muhamedin Rushiti
KEYWORDS
—Apolipoproteines, statin, total lipids, total cholesterol, tryglicerides. .
ABSTRACT
Disorders of lipid metabolism in patients with ESRD for the first time are described in 1827 by Dr. Bright, particularly in patients with nephrotic syndrome [4]. Replacing of physiological apolipoproteins with pathological and high degree of their influence in atherogenity are phenomena still undiscovered and therefore whitening of the above processes are necessary experimental and multicentric numerous studies with the most duration of research. Purpose of research paper is to assess the abnormalities(changes) of apolipoproteins in ESRD patients treated with repeated hemodialysis more than 7 years in Clinical Hospital Tetovo,Hemodialysis Unit,randomized by gender (male or female) and effects of hypolipidemic drugs (statins) on improvement of apolipoproteins abnormalities.Also importance has been given to HDL-ch metabolism disorder which is supposed that is responsible and main factor in controlling the progress and pace of atherogenesis mechanism in uremic patients.
References
[1] Allain CC., Poon LS., Chan CS., Richmond W, Enzymatic determination of total serum cholesterol, 6th Edition Clin. Chem, 20,470- 475(1974).

[2] Agarwal SK. et al. Prevalence of Chronic Renal Failure in adults in Delhi,India. Nephrol Dial Transplant 2005; (20) :1638-42.

[3] Bucola G., David H, Quantitative determination of serum triglycerides by use of enzymes. Clin. Chem, 19, 476- 482 (1973).

[4] Chan MK,Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int. 1981;(19): 119- 625.

[5] Crook, Errol D.MD; Thallapureddy, Anantha MD. Et al. Lipid abnormalitie and Renal disease: Is Dyslipidemia a Predictor of Progression of Renal Disease ?. Am J of the Medical Sciences: June 2003-Vol325-Issue 6- pp:340-348

[6] Dornbrook- Lavender KA et al. Effects of atorvastatin on lowdensity lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 25:335- 44,2005

[7] Lutfi Zylbeari. Profili i Dislipidemisë dhe Aberacionet e Apoproteineve te pacientët e Mjekuar me Hemodializë Perseritëse. Disertacioni i Doktoraturës. Shkup,2009.

[8] Landray M, Baigent C. et al. The second United Kingdom Heart and Renal Protection(UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47:385-395,2006 .

[9] Rao P, Reddy GC and Kanagasabapathy AS. MalnutitionInflammation-Atherosclerosis Syndrome in Chronic Kidney Disease. Indian Journal of Clinical Biochemistry,2008 (23) 209-217.

[10] Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17:2006-2016,2006

[11] Tilly P, et al. Biological and genetic determinants of serum apo CIII concentration: reference limits from the STANISLAS cohort study. J Lipid Res. 2003;44 :430-6.

Untitled Page